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Abstract
Background
Studies show that thousands of genes are associated with prognosis of breast cancer. To-
wards utilizing available genetic data, efforts have been made to predict outcomes using
gene expression data, and a number of commercial products have been developed. These
products have the following shortcomings: 1) They use the Cox model for prediction. How-
ever, the RSF model has been shown to significantly outperform the Cox model. 2) Testing
was not done to see if a complete set of clinical predictors could predict as well as the gene
expression signatures.
Methodology/Findings
We address these shortcomings. The METABRIC data set concerns 1981 breast cancer tu-
mors. Features include 21 clinical features, expression levels for 16,384 genes, and surviv-
al. We compare the survival prediction performance of the Cox model and the RSF model
using the clinical data and the gene expression data to their performance using only the clin-
ical data. We obtain significantly better results when we used both clinical data and gene ex-
pression data for 5 year, 10 year, and 15 year survival prediction. When we replace the
gene expression data by PAM50 subtype, our results are significant only for 5 year and 15
year prediction. We obtain significantly better results using the RSF model over the Cox
model. Finally, our results indicate that gene expression data alone may predict long-
term survival.
Conclusions/Significance
Our results indicate that we can obtain improved survival prediction using clinical data and
gene expression data compared to prediction using only clinical data. We further conclude
that we can obtain improved survival prediction using the RSF model instead of the Cox
model. These results are significant because by incorporating more gene expression data
with clinical features and using the RSF model, we could develop decision support systems
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that better utilize heterogeneous information to improve outcome prediction and
decision making.
Introduction
A clinical decision support system (CDSS) is a computer program, which is designed to assist
healthcare professionals and patients with making decisions such as treatment decisions for
cancer patients [1]. Studies show that thousands of genes are associated with subtype and prog-
nosis of breast cancer, and particular allele combinations may usefully guide the selection of ef-
fective treatment [2]. We have increasingly abundant data on cancer patients that includes
clinical features, genomic features, protein abundance, and gene expression. These sources of
data provide significant opportunities for developing CDSSs that utilize heterogeneous infor-
mation sources, such as clinical data and various types of genomic data, to improve outcome
prediction and clinical decision making over what is currently possible.
Towards utilizing the available genetic data, efforts have been to predict overall survival, re-
currence free survival, and risk of distant metastasis using gene expression data, and a number
of commercial products have been developed. An overview of these products appears in [3].
We review four of the more well-known products to set a context for the purpose of the re-
search presented in this paper.
In 2001 Sørlie et al. [4] established a now well-known classification system for breast cancer
tumors. Using a sample of 85 tumor samples, from a core set of 8,102 genes, they selected 1,753
genes whose expression varied by at least 4-fold from the median red/green ratio in at least three
or more of the samples. Hierarchical clustering was then used to group the gene profiles into 5
major subgroups: Lumina A, Lumina B, ERBB2+, Basal-like, and Normal breast-like. Using 49 of
the samples, they developed Kaplan-Meier plots showing overall survival and relapse-free survival
(RFS) for each of these subgroups. These Kaplan-Meir plots showed a significant difference in
both types of survival between the subgroups. This result only shows correlation. It does not indi-
cate predictive performance for the subgroups because there was no effort to predict survival for
a hold-out group (i.e. a group of samples that was not used to develop the plots).
These subtypes were later extensively studied [5–7]. In 2009 Parker et al. [8] performed
studies that led to the commercial product PAM50 [9] Using a sample of 189 tumors, they nar-
rowed down the number of genes needed to predict subclass to 50. Using this sample, They
learned Cox proportional hazard [10] RFS models using 1) only ER status, tumor size, and
grade; 2) only the subtype; 3) using the subtype and tumor size; and 4) using the subtype,
tumor size, and grade. The applied these models to a test data set consisting of 761 tumors. The
best results were obtained with subtype, tumor size, and grade (concordance index about equal
to 0.67), and the worst results were obtained with only ER status, tumor size, and grade (con-
cordance index about equal to 0.648). Parker et al. [8] conclude that the subgroup is an inde-
pendent predictor of survival, as also stated in the PAM50 brochure [9]. However, there are
many other clinical predictors of survival (See Table 1). To our knowledge, it has not been
shown that we obtain improved prediction performance when we use the PAM50 profile in ad-
dition to all relevant clinical variables.
In 2002 van `t Veer et al. [11] developed a 70 gene expression signature that predicts when
the time to distant metastases will be short for lymph node negative tumors. They obtained ex-
pression levels for about 25,000 genes from the tumors of 78 sporadic lymph-node negative
breast cancer patients. They then used a 3-step supervised classification method to narrow down
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the number of genes to 70. The signature correctly predicted the outcomes for 65 out of 78 pa-
tients. To validate the signature, the classifier was applied to 19 out-of-sample tumors; 17 out of
the 19 were correctly classified. This 70 gene classifier evolved into the commercial package
MammaPrint [12]. As far as we know, there have been no tests investigating whether equivalent
or better prediction could be done using clinical features such as those appearing in Table 1.
In 2004 Paik et al. [13] developed a 21 gene profile that predicts distant recurrence likeli-
hood in patients with breast cancer who have no lymph nodes involved and estrogen-positive
tumors. The list of 21 genes and the recurrence-score algorithm were developed by analyzing
the results of three independent preliminary studies involving 447 patients and 250 candidate
genes. The 21 genes include 16 cancer-related genes and 5 reference genes. They classified pa-
tients as low risk if the score was lower than 18, intermediate risk if it was between 18 and 31,
and high risk if it was greater than 31. They evaluated the score for tamoxifin-treated patients
who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial
B-14. Kaplan-Meier estimates for the patients in the low-risk group who were free of a distant
recurrence at 10 years (0.932) were significantly greater than the patients in the high-risk cate-
gory (0.695). This 21 gene profiling scheme led to the commercial package Oncotype DX [14],
which is intended to be used by women with early-stage, node-negative, ER+ invasive breast
cancer. It not only predicts recurrence but also estimates the likelihood of chemotherapy bene-
fit. To our knowledge, there have been no studies conducting whether this test yields improved
prediction performance over just using clinical variables like those listed in Table 1.
In 2011 Filibits et al. [15] predicted the likelihood of distant recurrence in ER+, HER2 nega-
tive breast cancer patients with adjuvant endocrine therapy. The system, which was developed
Table 1. The clinical variables used to predict survival.
Variable Description Values
age_at_diagnosis age at diagnosis of the disease 0–39, 39–54, 54–69, 69–84, 84–100
size size of tumor in cm 0–20, 20–50, 50–180
lymph_nodes_positive number of positive lymph nodes 0, 1, 2–3, 4–5, 6–9. 10
grade grade of disease 1, 2, 3
histological tumor histology IDC, IDC+ILC, IDC-TUB, IDC-MUC, IDC-MED, MIXED NST AND A
SPECIAL TYPE, OTHER, OTHER INVASIVE, INVASIVE TUMOR
ER_IHC_status ER status pos, neg
ER_Expr estrogen receptor expression +, -
PR_Expr progesterone receptor expression +, -
HER2_SNP6_state HER2 copy number gain or loss NEUT, GAIN, LOSS
HER2_Expr HER2 expression +, -
treatment Treatment None, HT, RT, CT, HT/RT, HT/CT, RT/CT, HT/RT/CT
inf_men_status inferred menopausal status pre, post
group characterizes patients by lymph node status, chemo-
and hormonal therapy
1, 2, 3, 4, other
stage composite of size and number of lymph nodes positive numeric
lymph_nodes_removed number of lymph nodes removed numeric
NPI the Nottingham Prognostic Index, a composite of tumor
size, number of lymph nodes positive, and grade
numeric
cellularity cells seen on histopathology high, low, moderate
Pam50_subtype subtype inferred from expression data for 50 genes Basal, Her2, LumA, LumB, NC, Normal
int_clust_memb cluster membership according to METABRIC 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
site collection site information specific to METABRIC 1, 2, 3, 4, 5
Genefu A composite of other variables used by METABRIC ER+/HER2-, High Prolif, Low Prolif, ER-/HER2-, HER2+
doi:10.1371/journal.pone.0117658.t001
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by analyzing 964 breast cancer patients, provides the Endopredict (EP) score obtained from 8
cancer-related genes and 3 normalization genes, tumor size, and the number of lymph nodes
involved. The score was validated using patients analyzed in the ABCSG translational research
program (abcsg.research). The validation groups were ABCSG-6 which contains 378 patients
and ABCSG-8 which contains 1,324 patients. Finally they used Cox regression to develop a pre-
diction model containing only the variables age, quantitative ER (HIC), and Ki67. Furthermore
they evaluated the Adjuvant!Online [16] score, which is obtained from clinical variables. In
tests using the same validation groups, they obtained better concordance indices using the EP
score than the other methods alone, and combinations of the other methods. Endopredict is
now a commercial package [17].
The EP score is different from the other methods discussed because it includes two clinical
features. Furthermore, it was shown to outperform clinical prediction using Adjuvant!Online.
However, it was not evaluated relative to a comprehensive list of clinical features like those
shown in Table 1.
The four methods just discussed, and other such methods, suffer from one or more of the
following difficulties: 1) They were developed and tested with fairly small data sets; 2) They
only apply to specialized subsets of patients; 3) As discussed in [11] these signatures do not al-
ways include genes widely believed to be involved in breast cancer. 4) They perform prediction
using the Cox proportional hazard model. However, the purpose of that model is more to iden-
tify covariates than to predict survival. The random survival forest method (RSF) [18] has been
shown to significantly outperform the Cox model in several studies [19,20]. 5) Most important-
ly, there was not sufficient testing to see if a complete set of clinical predictors could make the
same predictions as the gene expression signatures.
The studies presented here address the 4th and 5th issues. That is, we consider it still an open
question as to whether we can perform better outcome prediction utilizing high-dimensional
gene expression data in addition to clinical data. Specifically, we investigate whether a system
that uses both a complete set of clinical features and gene expression profiles can improve sur-
vival prediction relative to one that uses only a complete set of clinical features. Furthermore,
we investigate whether the random survival forest method outperforms the Cox model at can-
cer survival prediction.
TheMolecular Taxonomy of Breast Cancer International Consortium (METABRIC) data set
[21] has data on 1981 breast cancer tumors. Features include 21 clinical features, expression
levels for 16,384 genes, and overall survival. The objective of this investigation is to compare
the survival prediction performance of the Cox proportional hazards model and the RSF
model using the clinical data and the gene expression data in the METABRIC data set to their
performance using only the clinical data. The central hypotheses are 1) We can obtain better
survivorship prediction performance using both clinical features and gene expression data rela-
tive to using only clinical features; and 2) We can obtain better survivorship prediction using the
RSF model relative to using the Cox model.
Central to a CDSS for breast cancer patients is a component that predicts outcomes such as
overall survival, distant metastasis survival, local breast recurrence, and local lymph node re-
currence. Our ideal system would include all relative clinical variables and all relevant genetic
variables, and be applicable to all types of breast cancer. Our results are significant to the medi-
cal community because they help to answer the question as to whether gene expression data
would be useful to such a system, and whether it would be preferable to use the RSF model in-
stead of the Cox Model.
Since we evaluate the RSF and Cox model, we close this section by briefly reviewing them. A
survival prediction model learns a survival function from survival data. Such a function predicts
the probability of surviving past each point in time based on an individual’s covariates
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(predictors). For a given individual, the resultant function of time is called a survival curve. The
hazard function λ(t) is the probability of dying at time t given that one has not died before time
t. The hazard ratio is the ratio of λ(t) to a reference hazard function λ0(t). The Cox proportional
hazards model is a linear model for the log of the hazard ratio in terms of the covariates. When
we learn the survival function, we learn the linear coefficients of the covariates. The RSF model
works quite differently. A survival tree is a type of classification tree. Each node in a classifica-
tion tree makes a choice based on the value of a covariate until the leaf classifies the instance.
The tree is developed by starting at the root and determining the covariate that best identifies
the instance according to some criterion such as information gain. Recursively, the tree is then
built to the roots. In the RSF model,M bootstrap samples are obtained from the original data.
Each bootstrap sample excludes on the average 37% of the data. A survival tree is grown for
each bootstrap sample. At each node of the tree, N candidate covariates are randomly selected.
The node is split using the covariate that maximizes survival difference between daughter
nodes. The tree is grown until a leaf node has no less than D> 0 unique deaths. Finally, the cu-
mulative hazard function (CHF) is calculated for the tree. The average CHF is taken over all
bootstrap samples, and the prediction error is calculated using the data that was left out.
Methods
We evaluated survival prediction performance of the Cox proportional hazards model [10] and
the RSF model [18] using the METABRIC data set [21] which concerns primary breast tumors.
That data set has data on 1981 tumors. Features include 21 clinical features and expression lev-
els for 16,384 genes. TheMultiple Imputation with Diagnostics (MI) Package [22,23] was used
to impute missing values in the data set.
All gene expression levels were discretized to values low,medium, and high using the equal
width discretization technique, which discretizes the data into partitions ofM equally sized in-
tervals (M = 3 in our application).
Table 1 shows the clinical variables and their values used in our analysis. We transformed the
data in three of these variables from their original METABRIC values using a combination of domain
knowledge and the equal distribution discretization strategy. The transformations are as follows:
age_at_diagnosis: We discretized this variable to the ranges shown based on a combination of
the equal distribution discretization technique and breast cancer expert knowledge.
size: We discretized this variable to the three standard ranges shown.
lymph_nodes_positive: We grouped this variable into the six ranges shown.
Furthermore, the data set has the following two fields:
day: This field is a number of days.
status: This field's value is dead if the patient died day days after the initial consultation, and its
value is alive if the patient was last seen day days after initial consultation (and therefore
was known to be alive at that time).
Any patient, whose status field contains the value alive, is right censored. Right censored means
the patient left the study. All we know is that the patient was still alive the last time the patient was
seen. We created a table as shown in Table 2. Patient 2 was found to be dead in Year2. So Year2
and all subsequent years in Table 2 have value dead. Patient 3 was last seen in year 2, and was alive.
So we don't know the status of Patient 3 in subsequent years, and that patient is right censored.
The METABRIC data set contains the variable Pam50_subtype, which is the subtype in-
ferred from expression data for 50 genes as discussed above [8,9]. Since this variable is a
Prognostic Power of Gene Expression for Breast Cancer Survival
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composite of gene expression data, we removed it to obtain data that was only clinical. We call
that data set Clinical_Only. We obtained data including gene expression data in two ways. We
used all the clinical data in the METABRIC data set including Pam50_subtype. We call that
data set Clinical_PAM. We used the clinical data without Pam50_subtype, but with the expres-
sion levels of all 16,384 genes. We call that data set Clinical_Gene. We evaluated the Cox model
and the RSF model when they utilized these three data sets.
There are way too many genes to try to perform prediction using all of them directly when
utilizing Clinical_Gene. We limited the number of features by pre-processing the data set using
ReliefF. The ReliefF algorithm [24] ranks a set of possible predictor variables in terms of how
well they predict the target variable. This algorithm does not look at each predictor individual-
ly. Rather, it is aware of contextual information, and estimates predictive strength in light of a
predictor’s interactions with other predictors. The basic algorithm, called Relief assumes the
target variable is binary, and that there are no missing data. This is the situation in our studies.
These restrictions are removed in ReliefF, and you are referred to [24] for this more general al-
gorithm. We present the Relief algorithm that we used next.
Algorithm: Relief
Input: A set of data items. Each data item contains values of predictor variables and a value
of a binary target variable T.
Output: For each predictor F, a weightW[F] that estimates the predictive strength of F for T.
for each predictor F
W ½F  ¼ 0;
end for
repeat m times
randomly select a data item D;
determine nearest hit H to D;
determine nearest miss M to D;
for each predictor F
W ½F  ¼ W ½F   DiffðF ;D;HÞ=mþ DiffðF ;D;M Þ=m;
end for
end repeat
Table 2. A table developed from the METABRIC data set.
Patient X1 X2 . . . Xn Year1 Year2 Year3 . . . Year14 Year15
1 alive alive alive alive alive
2 alive dead dead dead dead
3 alive alive NA NA NA
. . .
doi:10.1371/journal.pone.0117658.t002
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The function Diff in Algorithm Relief is as follows;
Diff ðF;D;XÞ ¼ 0 if D and X have the same value for F;
1 otherwise:

By “nearest hit H to D”, we mean the data item H closest to D that has the same value of the
target as D; and by “nearest missM to D”, we mean the data itemM closest to D that has the
has a different value of the target than D. If D and H have different values for predictor F, then
F separates two close data items with the same value of the target, which indicates F is not a
good predictor; so we decrease the weight. On the other hand, if D andM have different values
for predictor F, then F separates two close data items with different values of the target, which
indicates F is a good predictor; so we increase the weight.
When ReliefF is employed, different sized sets of top predictive features can be used to per-
form prediction, and the set of features that yields the best performance is the one that is used
in the prediction system. We used sets of 30, 50, 100, and 150 top predictive features. We did
this in two ways:Method 1 combined the clinical features and the gene expression data, and
then used ReliefF to extract features.Method 2 extracted gene expression features from the
gene expression data, and then combined those features with all 21 clinical features. When
using this latter method, we only extracted 9, 29, 79, and 129 features so that the total number
of features was still 30, 50, 100, and 150.
We developed 5 year, 10 year, and 15 year survival functions using each of the methods. The
5 year survivor functions were learned only from survival information obtained from the first 5
years of post-initial visit information, the 10 year survivor functions were learned only from
the first 10 years of information, and the 15 year survivor functions were learned only from the
first 15 years of information. When using ReliefF, we used as our target survivorship at 5 years
to extract features for the 5 year survival functions, at 10 years to extract features for the 10
year survival functions, and at 15 years to extract features the 15 year survival functions. Note
that we did not utilize any assumed biological knowledge concerning which genes might be
good predictors. We relied only on machine learning to find good predictors. In this way our
results do not depend on any previous analyses.
In k-fold cross validation, we divide the data into k partitions of the same size. For each par-
tition j we learn a model using the data in the remaining k-1 partitions, and we then apply the
model to partition j. For each survival timeframe (5 year, 10 year, or 15 year) we compared
methods using 5-fold cross validation. Specifically, for each method, survival timeframe, and
partition, we learned a survival function from the individuals in the remaining 4 partitions. We
then used that function to develop a survival curve for each individual in the given partition.
Next, we computed the concordance for the individuals. The concordance index is the proba-
bility that, given two randomly drawn individuals, the individual who has the event first has a
worse survival curve. By “worse” we mean the area under the curve is smaller. To estimate the
concordance index, we pair each individual j known to be dead, with each individual k known
to be alive later than j or known to die later than j. Let areaj be the area under the survival curve
for individual j, and areak be the area under the survival curve for individual k. If areaj< areak,
we add 1 to a variable Total. Finally, we divide Total by the number of pairs to obtain the
concordance index. We statistically compared the concordance indexes for two methods using
the chi-square test.
Results
S1–S4 Tables show the raw results. That is, they show results for both Method 1 and Method 2,
and for all values of the number of features obtained from ReleifF.
Prognostic Power of Gene Expression for Breast Cancer Survival
PLOS ONE | DOI:10.1371/journal.pone.0117658 February 27, 2015 7 / 16
Table 3 and Fig. 1 compare the performances of the Cox model and the RSF model, while
showing only the best results for Clinical_Gene. For both the Cox model and the RSF model
these best results were obtained using Method 2. We see that the RSF model performs signifi-
cantly better (p< 2.2 × 10–16) than the Cox model in every case except for Clinical_Only
and 15 years, and this latter result is not significant. The most improvement for the RSF
model was realized with Clinical_Gene. The Cox model is based on linear regression and
does not do shrinkage to handle a large number of variables such as that done by a regularized
technique such as Lasso [25]. This would explain why it performs poorly when given many
features.
Table 3. Comparison of the Cox concordance index results and RSF concordance index results for
each type of data.
Year Clinical_Only Clinical_PAM Clinical_Gene
Cox RSF Cox RSF Cox RSF
5 0.709 0.714 0.713 0.721 0.703 (30) 0.720 (150)
10 0.718 0.723 0.720 0.724 0.719 (30) 0.731 (50)
15 0.694 .0692 0.698 0.705 0.696 (30) 0.706 (100)
For Clinical_Gene these are the best results obtained by the model. They were all obtained with Method
2. The number in parenthesis shows the number of features obtained from ReliefF that yielded the best
results. Other than the Year 15 entry for Clinical_Only, the comparison of the Cox results and RSF results is
significant at p < 2.2 × 10–16.
doi:10.1371/journal.pone.0117658.t003
Fig 1. Comparison of the Cox concordance index results and the RSF concordance index results for each type of data.
doi:10.1371/journal.pone.0117658.g001
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We are most interested in comparing the best results obtained for each data set over both mod-
els (Cox and RSF) and all values of the number of features provided to ReliefF because we would
use the best results in an actual prediction method. Table 4 and Fig. 2 show those results. Clinical_
Gene performs significantly better than Clinical_Only for all values of Year (p< 2.2 × 10–16).
Clinical_Pam performs about as well as Clinical_Gene for 5 years and 15 years, but barely per-
forms better than Clinical_Only for 10 years.
Our chief purpose was to investigate whether we would obtain better performance by in-
cluding gene expression data and by using the RSF model instead of using only clinical data
and using the Cox model. Table 5 and Fig. 3 compare the two. We see that Clinical_Gene using
the RSF models is up to almost 2% more accurate than Clinical_Only using the Cox model.
Our studies were done using 5-fold cross validation. In general, if we were to then use the
method in an actual production system, we would learn from the entire data set. S5 Table
shows the top 150 features extracted by ReliefF from the entire data set for Method 1 and
Method 2, and for 5 year, 10 year, and 15 year prediction. We obtained our best overall results
using the RSF model and Method 2, and using 150 genes for 5 year prediction, 50 genes for 10
Table 4. Comparison of the best concordance index results obtained for each data set over both models (Cox and RSF) and all values of the
number of features provided to ReliefF.
Year Clinical_Only Clinical_PAM Clinical_Gene p-value PAM p-value Gene
5 0.714 0.721 0.720 1.17×10–14 6.77×10–14
10 0.723 0.724 0.731 0.251 < 2.2 × 10–16
15 0.694 0.705 0.706 p < 2.2 × 10–16 < 2.2 × 10–16
The 5th column shows the p-values obtained when Clinical_Only is compared to Clinical_PAM. The 6th column shows the p-value when Clinical_Only is
compared to Clinical_Gene.
doi:10.1371/journal.pone.0117658.t004
Fig 2. Comparison of the best results obtained for each data set over both models (Cox and RSF) and all values of the number of features provided
to ReliefF.
doi:10.1371/journal.pone.0117658.g002
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year prediction, and 100 genes for 15 year prediction. Figs. 4, 5, and 6 show heat maps concern-
ing these top genes when ReliefF learns from the entire data set. These heat maps were created
using the software package Partek (http://www.partek.com/), which allows one to perform ei-
ther hierarchical clustering or partition clustering. Hierarchical clustering break up the data in
to a hierarchy of clusters. Partitional clustering divided the data into mutually disjoint parti-
tions. We did partition clustering for the individuals on the y-axis and hierarchical clustering
for the genes on the x-axis. In Figs. 4–6 we also show the individuals in each cluster who sur-
vived and did not survive. These results are consistent with Table 4, which shows that Clini-
cal_Gene exhibits the least improvement relative to Clinical_Only in the case of 5 year survival
prediction. Looking at the 5 year survival heat map in Fig. 4, we see that the fraction of individ-
uals not surviving is the not much different in the three clusters. However, the 10 year survival
heat map in Fig. 5 shows that individuals in Cluster 1 are much less likely to survive than indi-
viduals in the other two clusters. Similarly, the 15 year survival heat map in Fig. 5 shows that
individuals in Clusters 1 and 3 are less likely to survive than individuals in Cluster 2.
It is interesting to investigate which genes were found to be predictive for two or more time
frames. Table 6 shows the genes, from the top 150 genes extracted by ReliefF, which the time
Table 5. Comparison of the best concordance index results obtained using Clinical_Gene and the RSF model to the concordance index results
obtained using Clinical_Only and the Cox model.
Year Clinical_Only/Cox Clinical_Gene/RSF Percent Increase
5 0.709 0.720 0.015
10 0.718 0.731 0.018
15 0.694 0.706 0.017
All results are significant at p < 2.2 × 10–16.
doi:10.1371/journal.pone.0117658.t005
Fig 3. Comparison of the best concordance index results obtained usingClinical_Gene and the RSFmodel to the concordance index results
obtained usingClinical_Only and the Coxmodel.
doi:10.1371/journal.pone.0117658.g003
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frame pairs have in common. Time frames 5 year and 10 year share 18 predictive genes, time
frames 10 year and 15 year share 12 predictive genes, and time frames 5 year and 15 year share
only 2 predictive genes. All three time frames share only the predictive genes MND1 and
CKAP2L. TheMND1 gene has been shown to be essential for meiotic recombination between
homologous chromosomes [26]. Its disruption results in severe defects in homologous chro-
mosome synapsis and an early-stage failure in meiotic recombination. CKAP2L has recently
been shown to be an independent prognostic marker for RFS in early-stage breast cancer [27].
The fact that the 5 year and 10 year timeframes share so few genes is interesting in its own
right, and indicates that many genes related to short term survival might be different from
those related to long term survival.
It is also revealing to investigate the clinical features chosen by Method 1. Table 7 shows
them. In the case of both 5 year and 10 year survival, lymph_nodes_positive and group are the
top two features. However, in 15 year survival, lymph_nodes_positive does not appear at all,
and there is only one clinical feature in the top 50 features. That feature is the Nottingham prog-
nostic index (NPI), which is calculated using the size of the lesion, the number of lymph nodes
involved, and the grade of the tumor; and which therefore includes the information in the fea-
ture lymph_nodes_positive. A similar situation holds for the 15 year survival training sets (not
shown). Namely, NPI is the top clinical feature in all of them, and its average location is 25th.
Only one of them has another clinical feature (“group” which appears 11th) in the top 50 fea-
tures, and one has no clinical features in the top 50 features. Yet, as we can see from S2 Table,
Fig 4. Heat map clustering 1981 breast cancer tumors and the top 150 genes learned using ReliefF from the entire data set for 5 year survival
prediction.
doi:10.1371/journal.pone.0117658.g004
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we can get fairly good prediction (concordance index equal to 0.654) using the top 50 features.
This result indicates we may be able to predict much of long term survival using gene
expression signatures.
Discussion
We compared survival prediction using both clinical data and gene expression data to survival
prediction using only clinical data. We obtained significantly better results when we used both
clinical data and gene expression data relative to when we used only clinical data. When we in-
cluded Pam50_subtype, which is a composite of the expression data for 50 genes, with the clini-
cal features, our results were significantly better only for 5 year and 15 year prediction. When
we used ReliefF to choose good gene expression predictors, the results were significant for 5
years, 10 year, and 15 year prediction. This information is meaningful because often 10 year
survival is the most utilized survival criterion.
We also compared survival prediction using both the Cox model and the RSF model, and
we obtained significantly better performance using the RSF model. This result is also notable
because the Cox model is often used to do survival prediction in current systems (as noted in
the Introduction Section). Furthermore, our results indicate that the Cox model cannot handle
a large number of covariates, and might explain why existing methods (as discussed in the
Background Section) limit the number of genes or group them into subtypes. As noted in the
Fig 5. Heat map clustering 1981 breast cancer tumors and the top 50 genes learned using ReliefF from the entire data set for 10 year survival
prediction.
doi:10.1371/journal.pone.0117658.g005
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Introduction Section, studies show that thousands of genes are associated with subtype and
prognosis of breast cancer [2]. As also noted, current signatures do not always include genes
widely believed to be involved in breast cancer [11]. With the power of the RSF model, we can
possibly include all relevant features and improve prediction.
Our results indicate that we can improve prediction performance by using gene expression
date beyond the subtype composites in PAM50. Future research can investigate feature selec-
tion further. First, we can investigate whether we get similar, or even improved, results using
strategies other than ReliefF to locate good predictors. For example, we could use the Bayesian
network-based methods that look for interacting causes of a target [28]. We can investigate
how gene expression data and clinical features might interact. We can see if the RSF method re-
mains better than the Cox method when these other strategies are used. Second, we can investi-
gate whether we can improve prediction further by including copy number variations (CNV)
and copy number alterations (CNA). We can utilize both machine learning knowledge and bio-
logical knowledge in our choice of genetic features. Finally, since we have learned that the pre-
diction method which is used can make a substantial difference, we can investigate using other
survival prediction methods such as the recently developed Bayesian network based method
S_EBMC [28].
We obtained an interesting result when we applied ReliefF in Method 1 to simultaneously
learn good clinical and gene expression predictors. That is, our results show that very few clini-
cal features are needed for 15 year prediction. This would indicate that much of long-term
Fig 6. Heat map clustering 1981 breast cancer tumors and the top 100 genes learned using ReliefF from the entire data set for 15 year survival
prediction.
doi:10.1371/journal.pone.0117658.g006
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survival can be explained by gene expression signatures. If someone survives long-term, it is
likely they died of something other than breast cancer (although our data is not able to support
this claim). So, perhaps long-term survival in general can be predicted by gene expression sig-
natures, which opens the possibility of increasing longevity by targeting gene expression.
Supporting Information
S1 Table. Concordance index results for the Cox model Using Method 1.
(DOC)
S2 Table. Concordance index results for the RSF model Using Method 1.
(DOC)
Table 6. The predictive genes, from the top 150 genes extracted by ReliefF, that the time frame pairs
have in common.
5 / 10 year 5 / 15 year 10 / 15 year
OR2AG1 MND1 MND1
EGFL7 CKAP2L CDKN3
SLC30A8 PTTG3P
RRM2 PRC1
MND1 RACGAP1
HSPB1 NCOA3
C2 HMGCS1
FANCE CKAP2L
OSBPL1A CDCA5
CEBPG CEP55
F2RL3 KIF4A
CCNA2 SFRP1
CKAP2L
PTK2B
C7orf41
CD84
CD4
DSCC1
doi:10.1371/journal.pone.0117658.t006
Table 7. The clinical features extracted by ReliefF in the case of Method 1.
5 Year 10 Year 15 Year
Rank Feature Rank Feature Rank Feature
1 lymph_nodes_positive 1 group 5 NPI
2 group 2 lymph_nodes_positive 77 group
49 stage 3 NPI 129 treatment
110 size 12 size 138 int_clust_memb
14 site
102 stage
145 age_at_diagnosis
The Rank is where the feature occurs in the top 150 features.
doi:10.1371/journal.pone.0117658.t007
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S3 Table. Concordance index results for the Cox model Using Method 2.
(DOC)
S4 Table. Concordance index results for the RSF model Using Method 2.
(DOC)
S5 Table. Lists of the 150 features extracted by ReliefF for Methods 1 and 2 and for 5 year,
10 year, and 15 year prediction.
(XLSX)
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